NH
$243.07
+7.47
(+3.17%)
As of Oct 22, 2026, 9:33 PM EDT · cached
Price history
National Healthcare Corp (NHC) is trading up at $243.07 (+3.17%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
National Healthcare Corp revenue & net income history (FY2016–FY2025)
RevenueNet incomeNet margin (right axis, %)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $923.6M | $963.9M | $980.3M | $996.4M | $1.03B | $1.07B | $1.09B | $1.14B | $1.31B | $1.52B |
| Growth (year over year) | — | +4.4% | +1.7% | +1.6% | +3.2% | +4.5% | +1.1% | +5.1% | +14.5% | +16.1% |
| Operating income | $60.5M | $54.1M | $56.1M | $49.0M | $48.2M | $50.9M | $31.9M | $57.5M | $89.9M | $128.4M |
| Operating margin | 6.6% | 5.6% | 5.7% | 4.9% | 4.7% | 4.7% | 2.9% | 5.0% | 6.9% | 8.5% |
| Net income | $50.5M | $56.2M | $59.0M | $68.2M | $41.9M | $138.6M | $22.4M | $66.8M | $101.9M | $120.0M |
| Net margin | 5.5% | 5.8% | 6.0% | 6.8% | 4.1% | 12.9% | 2.1% | 5.9% | 7.8% | 7.9% |
| EPS (diluted) | $3.32 | $0.04 | $3.87 | $4.44 | $2.72 | $8.99 | $1.45 | $4.34 | $6.53 | $7.67 |
| Balance sheet | ||||||||||
| Cash and equivalents | $26.3M | $59.1M | $43.2M | $50.3M | $147.1M | $107.6M | $58.7M | $107.1M | $76.1M | $92.8M |
| Total assets | $1.09B | $1.10B | $1.08B | $1.29B | $1.36B | $1.40B | $1.28B | $1.31B | $1.52B | $1.53B |
| Total liabilities | $417.8M | $393.1M | $346.5M | $507.6M | $563.9M | $494.9M | $397.9M | $400.3M | $541.3M | $451.9M |
| Long-term debt | $120.0M | $100.0M | $55.0M | $0 | — | — | — | $0 | $129.5M | $32.5M |
| Shareholders' equity | $669.6M | $702.7M | $733.3M | $778.6M | $795.2M | $903.0M | $874.3M | $908.8M | $980.2M | $1.07B |
| Cash flow | ||||||||||
| Operating cash flow | $90.9M | $94.5M | $98.4M | $100.1M | $203.3M | $62.4M | $8.74M | $111.2M | $107.3M | $185.1M |
| Capital expenditure | $62.6M | $32.3M | $29.8M | $26.4M | $21.9M | $39.4M | $30.2M | $27.9M | $27.6M | $36.4M |
| Free cash flow | $28.3M | $62.1M | $68.7M | $73.7M | $181.4M | $23.0M | −$21.5M | $83.3M | $79.7M | $148.6M |
| Dividends paid | $25.8M | $28.2M | $29.8M | $31.2M | $31.9M | $32.0M | $34.6M | $35.6M | $37.0M | $38.7M |
| Share buybacks | $8.20M | $0 | $867.0K | $872.0K | $53.0K | $836.0K | $9.90M | $2.48M | $13.5M | $14.7M |
RevenueNet incomeNet margin (right axis, %)
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $340.2M | $369.4M | $373.7M | $374.9M | $382.7M | $386.5M | $381.8M | $408.0M |
| Growth (year over year) | +17.9% | +22.7% | +25.7% | +24.7% | +12.5% | +4.6% | +2.2% | +8.8% |
| Operating income | $22.8M | $28.9M | $30.8M | $34.1M | $30.4M | $33.1M | $32.3M | $48.9M |
| Operating margin | 6.7% | 7.8% | 8.2% | 9.1% | 7.9% | 8.6% | 8.4% | 12.0% |
| Net income | $42.8M | $6.08M | $32.2M | $23.7M | $39.2M | $24.8M | $35.9M | $40.3M |
| Net margin | 12.6% | 1.6% | 8.6% | 6.3% | 10.3% | 6.4% | 9.4% | 9.9% |
| EPS (diluted) | $2.73 | $0.38 | $2.07 | $1.52 | $2.50 | $1.58 | $2.27 | $2.54 |
| Balance sheet | ||||||||
| Cash and equivalents | $84.8M | $76.1M | $90.4M | $111.0M | $130.6M | $92.8M | $85.5M | $39.2M |
| Total assets | $1.56B | $1.52B | $1.55B | $1.56B | $1.57B | $1.53B | $1.52B | $1.54B |
| Total liabilities | $575.9M | $541.3M | $540.8M | $536.8M | $513.9M | $451.9M | $427.5M | $408.9M |
| Long-term debt | $129.5M | $129.5M | $126.5M | $102.5M | $65.6M | $32.5M | $0 | $0 |
| Shareholders' equity | $983.5M | $980.2M | $1.00B | $1.02B | $1.05B | $1.07B | $1.09B | $1.12B |
| Cash flow | ||||||||
| Operating cash flow | $34.2M | $12.8M | $39.3M | $62.8M | $66.2M | $16.8M | $62.5M | $43.3M |
| Capital expenditure | $5.66M | $8.16M | $6.14M | $10.2M | $9.71M | $10.4M | $9.64M | $12.5M |
| Free cash flow | $28.6M | $4.63M | $33.1M | $52.6M | $56.5M | $6.41M | $52.9M | $30.7M |
| Dividends paid | $9.41M | $9.42M | $9.42M | $9.43M | $9.92M | $9.93M | $9.94M | $9.99M |
| Share buybacks | $2.10M | $0 | $1.72M | $4.66M | $3.18M | $5.16M | $16.3M | $7.24M |
From National Healthcare Corp's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About National Healthcare Corp
- Headquarters
- Murfreesboro, Tennessee From SEC filings, Oct 2026
Recent News (4)
-
National Healthcare Properties Head of Senior Housing Named to ASHA Executive Board NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- National Healthcare Properties, Inc. (Nasdaq: NHP) (“NHP”) announced today that Lindsay Gordon, Executive Vice President and Head of Senior Housing, has b…
-
CSG Government Solutions' Sean Kasten Named Among Top Healthcare Consultants and Leaders of 2026 by The Consulting Report CHICAGO, Oct. 14, 2026 /PRNewswire/ -- CSG Government Solutions, a national leader in government program modernization, today announced that Sean Kasten, Vice President and National Healthcare and Hum…
-
Cardinal Health Loses Multiple "Product Return" Lawsuits Against Pharmacy Customers and Pays Attorneys' Fees to Settle Sanctions Motion for Frivolous Litigation Health Law Alliance has secured the dismissal of three lawsuits filed by Cardinal Health against its own customers for breach of the distributor's drug return program. MILLBURN, N.J., Sept. 16, 2026 /…
-
Chevron shares advance 1.7% after NHC lowers immediate storm risk to 20% Chevron shares advance 1.7% after NHC lowers immediate storm risk to 20% TechStock²
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International